Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Growth · Royce

Royce Smaller-Companies Growth Fund Service Class (RYVPX)

Ticker RYVPX · · Holdings as of Jun 30, 2026

Expense ratio
1.49%$149/yr per $10k
5-yr return
+4.4%annualized
1-yr return
+19.3%as of Dec 2025
Net assets
$238.4Mall share classes
Holdings
84

Bottom line

Is RYVPX a good fund? The bottom line

RYVPX is the Service Class share class of Royce Smaller-Companies Growth Fund, a managed large growth mutual fund from Royce.

Annual fees run 1.49% — about $149 a year on every $10,000 invested, more expensive than 88% of large growth funds we track.

It returned +19.3% over one year, +4.4% a year over five years, +10.2% a year over ten (as of Dec 31, 2025, per its prospectus).

With $238 million in net assets and 84 holdings, its largest position is Fixed Income Clearing Corp. (6.2%) and the top 10 make up 30.5% of the portfolio.

What stands out

  • No front-end sales load

What to watch

  • Expensive for its category (1.49%)
  • 5-year return in the bottom quarter of its category
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What RYVPX invests in

Royce Smaller-Companies Growth Funds investment goal is long-term growth of capital.

Royce Investment Partners (Royce), the Funds investment adviser, invests the Funds assets primarily in equity securities of companies with stock market capitalizations up to $7.5 billion that it believes have above-average growth prospects. Royce also considers the extent to which such companies are trading below its estimate of their current worth and/or have the potential for higher internal rates of return or improved profit margins. The Fund invests at least 80% of its net assets in equity securities of companies with stock market capitalizations up to $7.5 billion, under normal circumstances. The Fund may continue to hold or, in some cases, build positions in companies with market capitalizations of more than $7.5 billion. Although the Fund generally focuses on securities of U.S. companies, it may invest up to 25% of its net assets (measured at the time of investment) in equity…

From the fund's prospectus (filed Apr 30, 2026).

RYVPX performance

Fund calendar-year total returns, 2016–2025 2016: +9.4%; 2017: +17.8%; 2018: −10.2%; 2019: +23.7%; 2020: +49.3%; 2021: +7.8%; 2022: −3,240.0%; 2023: +17.0%; 2024: +21.8%; 2025: +19.3% +9% 2016 +18% 2017 −10% 2018 +24% 2019 +49% 2020 +8% 2021 −3,240% 2022 +17% 2023 +22% 2024 +19% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
RYVPX+19.3%+4.4%+10.2%
Large Growth median+15.2%+11.0%+14.2%

Source: Fund prospectus, as of Dec 31, 2025

Full RYVPX performance history →

What RYVPX costs

On a $10,000 investment, RYVPX's 1.49% expense ratio costs about $149 a year. The prospectus estimates $1,861 in total costs over 10 years (assuming 5% annual returns). The median large growth fund charges 0.87%.

See the full RYVPX fee table →

RYVPX top 10 holdings

#Holding% of fund
1Fixed Income Clearing Corp.6.18%
2Hinge Health Inc3.05%
3Definium Therapeutics Inc2.98%
4Magnite Inc2.83%
5Flotek Industries Inc2.71%
6Axsome Therapeutics Inc2.70%
7ACV Auctions Inc2.63%
8Strata Critical Medical Inc2.62%
9Impinj Inc2.51%
10Federated Government Obligations Fund2.36%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 30.5% of the fund. See all top 25 holdings and asset mix →

Alternatives to RYVPX

More funds like RYVPX →

RYVPX FAQ

What is the expense ratio of RYVPX?
RYVPX's expense ratio is 1.49%, which works out to about $149 a year for every $10,000 invested. The prospectus estimates total costs of $1,861 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is RYVPX a good investment?
It depends on your goals, but the data points to: no front-end sales load; expensive for its category (1.49%); 5-year return in the bottom quarter of its category; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does RYVPX hold?
RYVPX's largest holdings are Fixed Income Clearing Corp. (6.2%), Hinge Health Inc (3.0%), Definium Therapeutics Inc (3.0%), Magnite Inc (2.8%), Flotek Industries Inc (2.7%). It holds 84 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is RYVPX's 5-year return?
RYVPX returned +4.4% a year over the five years ending Dec 31, 2025, and +10.2% a year over ten years. Past performance does not guarantee future results.
Does RYVPX have a sales load?
No. RYVPX has no front-end sales charge.
Who manages RYVPX?
RYVPX is offered by Royce through Royce Fund.